Journal of Gastric Cancer

The Korean Gastric Cancer Association (대한위암학회)
권호 표지
DOI QR코드

DOI QR Code

Imaging of Gastric Cancer Metabolism Using 18 F-FDG PET/CT

  • Yun, Mijin (Department of Nuclear Medicine, Yonsei University College of Medicine)
  • Received : 2013.12.03
  • Accepted : 2013.12.22
  • Published : 2014.03.31
Download PDF
⟨ Previous Next ⟩

Abstract

Aerobic glycolysis has been the most important hypothesis in cancer metabolism. It seems to be related to increased bioenergetic and biosynthetic needs in rapidly proliferating cancer cells. To this end, F-18 fluorodeoxyglucose (FDG), a glucose analog, became widely popular for the detection of malignancies combined with positron emission tomography/computed tomography (PET/CT). Although the potential roles of FDG PET/CT in primary tumor detection are not fully established, it seems to have a limited sensitivity in detecting early gastric cancer and mainly signet ring or non-solid types of advanced gastric cancer. In evaluating lymph node metastases, the location of lymph nodes and the degree of FDG uptake in primary tumors appear to be important factors affecting the diagnostic accuracy of PET/CT. In spite of the limited sensitivity, the high specificity of PET/CT for lymph node metastases may play an important role in changing the extent of lymphadenectomy or reducing futile laparotomies. For peritoneal metastases, PET/CT seems to have a poorer sensitivity but a better specificity than CT. The roles of PET/CT in the evaluation of other distant metastases are yet to be known. Studies including primary tumors with low FDG uptake or peritoneal recurrence seem suffer from poorer diagnostic performance for the detection of recurrent gastric cancer. There are only a few reports using FDG PET/CT to predict response to neoadjuvant or adjuvant chemotherapy. A complete metabolic response seems to be predictive of more favorable prognosis.

Keywords

References

  1. Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. J Gen Physiol 1927;8:519-530. https://doi.org/10.1085/jgp.8.6.519
  2. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-674. https://doi.org/10.1016/j.cell.2011.02.013
  3. Stahl A, Ott K, Weber WA, Becker K, Link T, Siewert JR, et al. FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings. Eur J Nucl Med Mol Imaging 2003;30:288-295. https://doi.org/10.1007/s00259-002-1029-5
  4. Mochiki E, Kuwano H, Katoh H, Asao T, Oriuchi N, Endo K. Evaluation of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography for gastric cancer. World J Surg 2004;28:247-253. https://doi.org/10.1007/s00268-003-7191-5
  5. Yun M, Lim JS, Noh SH, Hyung WJ, Cheong JH, Bong JK, et al. Lymph node staging of gastric cancer using (18)F-FDG PET: a comparison study with CT. J Nucl Med 2005;46:1582-1588.
  6. Chen J, Cheong JH, Yun MJ, Kim J, Lim JS, Hyung WJ, et al. Improvement in preoperative staging of gastric adenocarcinoma with positron emission tomography. Cancer 2005;103:2383-2390. https://doi.org/10.1002/cncr.21074
  7. Kim SK, Kang KW, Lee JS, Kim HK, Chang HJ, Choi JY, et al. Assessment of lymph node metastases using 18F-FDG PET in patients with advanced gastric cancer. Eur J Nucl Med Mol Imaging 2006;33:148-155. https://doi.org/10.1007/s00259-005-1887-8
  8. Mukai K, Ishida Y, Okajima K, Isozaki H, Morimoto T, Nishiyama S. Usefulness of preoperative FDG-PET for detection of gastric cancer. Gastric Cancer 2006;9:192-196. https://doi.org/10.1007/s10120-006-0374-7
  9. Herrmann K, Ott K, Buck AK, Lordick F, Wilhelm D, Souvatzoglou M, et al. Imaging gastric cancer with PET and the radiotracers 18F-FLT and 18F-FDG: a comparative analysis. J Nucl Med 2007;48:1945-1950. https://doi.org/10.2967/jnumed.107.044867
  10. Kameyama R, Yamamoto Y, Izuishi K, Takebayashi R, Hagiike M, Murota M, et al. Detection of gastric cancer using 18F-FLT PET: comparison with 18F-FDG PET. Eur J Nucl Med Mol Imaging 2009;36:382-388. https://doi.org/10.1007/s00259-008-0970-3
  11. Kim EY, Lee WJ, Choi D, Lee SJ, Choi JY, Kim BT, et al. The value of PET/CT for preoperative staging of advanced gastric cancer: comparison with contrast-enhanced CT. Eur J Radiol 2011;79:183-188. https://doi.org/10.1016/j.ejrad.2010.02.005
  12. Yun M, Choi HS, Yoo E, Bong JK, Ryu YH, Lee JD. The role of gastric distention in differentiating recurrent tumor from physiologic uptake in the remnant stomach on 18F-FDG PET. J Nucl Med 2005;46:953-957.
  13. Kamimura K, Nagamachi S, Wakamatsu H, Fujita S, Nishii R, Umemura Y, et al. Role of gastric distention with additional water in differentiating locally advanced gastric carcinomas from physiological uptake in the stomach on 18F-fluoro-2-deoxy-D-glucose PET. Nucl Med Commun 2009;30:431-439. https://doi.org/10.1097/MNM.0b013e3283299a2f
  14. Takahashi H, Ukawa K, Ohkawa N, Kato K, Hayashi Y, Yoshimoto K, et al. Significance of (18)F-2-deoxy-2-fluoro-glucose accumulation in the stomach on positron emission tomography. Ann Nucl Med 2009;23:391-397. https://doi.org/10.1007/s12149-009-0255-3
  15. Yoshioka T, Yamaguchi K, Kubota K, Saginoya T, Yamazaki T, Ido T, et al. Evaluation of 18F-FDG PET in patients with advanced, metastatic, or recurrent gastric cancer. J Nucl Med 2003;44:690-699.
  16. De Potter T, Flamen P, Van Cutsem E, Penninckx F, Filez L, Bormans G, et al. Whole-body PET with FDG for the diagnosis of recurrent gastric cancer. Eur J Nucl Med Mol Imaging 2002;29:525-529. https://doi.org/10.1007/s00259-001-0743-8
  17. Chung HW, Lee EJ, Cho YH, Yoon SY, So Y, Kim SY, et al. High FDG uptake in PET/CT predicts worse prognosis in patients with metastatic gastric adenocarcinoma. J Cancer Res Clin Oncol 2010;136:1929-1935. https://doi.org/10.1007/s00432-010-0852-5
  18. Pak KH, Yun M, Cheong JH, Hyung WJ, Choi SH, Noh SH. Clinical implication of FDG-PET in advanced gastric cancer with signet ring cell histology. J Surg Oncol 2011;104:566-570. https://doi.org/10.1002/jso.21997
  19. Park JC, Lee JH, Cheoi K, Chung H, Yun MJ, Lee H, et al. Predictive value of pretreatment metabolic activity measured by fluorodeoxyglucose positron emission tomography in patients with metastatic advanced gastric cancer: the maximal SUV of the stomach is a prognostic factor. Eur J Nucl Med Mol Imaging 2012;39:1107-1116. https://doi.org/10.1007/s00259-012-2116-x
  20. Lee JW, Lee SM, Lee MS, Shin HC. Role of 18F-FDG PET/CT in the prediction of gastric cancer recurrence after curative surgical resection. Eur J Nucl Med Mol Imaging 2012;39:1425-1434. https://doi.org/10.1007/s00259-012-2164-2
  21. Yang QM, Kawamura T, Itoh H, Bando E, Nemoto M, Akamoto S, et al. Is PET-CT suitable for predicting lymph node status for gastric cancer? Hepatogastroenterology 2008;55:782-785.
  22. Lim JS, Kim MJ, Yun MJ, Oh YT, Kim JH, Hwang HS, et al. Comparison of CT and 18F-FDG pet for detecting peritoneal metastasis on the preoperative evaluation for gastric carcinoma. Korean J Radiol 2006;7:249-256. https://doi.org/10.3348/kjr.2006.7.4.249
  23. Smyth E, Schoder H, Strong VE, Capanu M, Kelsen DP, Coit DG, et al. A prospective evaluation of the utility of 2-deoxy-2-[(18) F]fluoro-D-glucose positron emission tomography and computed tomography in staging locally advanced gastric cancer. Cancer 2012;118:5481-5488. https://doi.org/10.1002/cncr.27550
  24. Jadvar H, Tatlidil R, Garcia AA, Conti PS. Evaluation of recurrent gastric malignancy with [F-18]-FDG positron emission tomography. Clin Radiol 2003;58:215-221. https://doi.org/10.1016/S0009-9260(02)00477-4
  25. Nakamoto Y, Togashi K, Kaneta T, Fukuda H, Nakajima K, Kitajima K, et al. Clinical value of whole-body FDG-PET for recurrent gastric cancer: a multicenter study. Jpn J Clin Oncol 2009;39:297-302. https://doi.org/10.1093/jjco/hyp010
  26. Park MJ, Lee WJ, Lim HK, Park KW, Choi JY, Kim BT. Detecting recurrence of gastric cancer: the value of FDG PET/CT. Abdom Imaging 2009;34:441-447. https://doi.org/10.1007/s00261-008-9424-4
  27. Sohn YJ, Jang JS, Choi SR, Kwon HC, Jung GJ, Kim MC, et al. Early detection of recurrence after endoscopic treatment for early gastric cancer. Scand J Gastroenterol 2009;44:1109-1114.
  28. Sim SH, Kim YJ, Oh DY, Lee SH, Kim DW, Kang WJ, et al. The role of PET/CT in detection of gastric cancer recurrence. BMC Cancer 2009;9:73. https://doi.org/10.1186/1471-2407-9-73
  29. Lee JE, Hong SP, Ahn DH, Jeon TJ, Kang MK, Kwon CI, et al. The role of 18F-FDG PET/CT in the evaluation of gastric cancer recurrence after curative gastrectomy. Yonsei Med J 2011;52:81-88. https://doi.org/10.3349/ymj.2011.52.1.81
  30. Bilici A, Ustaalioglu BB, Seker M, Kefeli U, Canpolat N, Tekinsoy B, et al. The role of 18F-FDG PET/CT in the assessment of suspected recurrent gastric cancer after initial surgical resection: can the results of FDG PET/CT influence patients' treatment decision making? Eur J Nucl Med Mol Imaging 2011;38:64-73. https://doi.org/10.1007/s00259-010-1611-1
  31. Ott K, Fink U, Becker K, Stahl A, Dittler HJ, Busch R, et al. Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. J Clin Oncol 2003;21:4604-4610. https://doi.org/10.1200/JCO.2003.06.574
  32. Ott K, Herrmann K, Lordick F, Wieder H, Weber WA, Becker K, et al. Early metabolic response evaluation by fluorine-18 fluorodeoxyglucose positron emission tomography allows in vivo testing of chemosensitivity in gastric cancer: long-term results of a prospective study. Clin Cancer Res 2008;14:2012-2018. https://doi.org/10.1158/1078-0432.CCR-07-0934
  33. Di Fabio F, Pinto C, Rojas Llimpe FL, Fanti S, Castellucci P, Longobardi C, et al. The predictive value of 18F-FDG-PET early evaluation in patients with metastatic gastric adenocarcinoma treated with chemotherapy plus cetuximab. Gastric Cancer 2007;10:221-227. https://doi.org/10.1007/s10120-007-0438-3

Cited by

  1. Analysis of surgery for incurable gastric cancer vol.13, pp.None, 2014, https://doi.org/10.1186/s12957-015-0750-z
  2. 18 F-FDG PET/CT Role in Staging of Gastric Carcinomas: Comparison with Conventional Contrast Enhancement Computed Tomography vol.94, pp.20, 2014, https://doi.org/10.1097/md.0000000000000864
  3. Appropriateness criteria of FDG PET/CT in oncology vol.25, pp.2, 2014, https://doi.org/10.4103/0971-3026.155823
  4. Relationship Between 18F-FDG Uptake on PET and Recurrence Patterns After Curative Surgical Resection in Patients with Advanced Gastric Cancer vol.56, pp.10, 2014, https://doi.org/10.2967/jnumed.115.160580
  5. Preclinical Positron Emission Tomographic Imaging of Acute Hyperoxia Therapy of Chronic Hypoxia during Pregnancy vol.14, pp.7, 2014, https://doi.org/10.2310/7290.2015.00013
  6. Laparoscopy, computerised tomography and fluorodeoxyglucose positron emission tomography in the management of gastric and gastro-oesophageal junction cancers vol.30, pp.7, 2014, https://doi.org/10.1007/s00464-015-4590-2
  7. Prognostic value of 18F-fluorodeoxyglucose positron emission tomography in patients with gastric neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma vol.30, pp.4, 2016, https://doi.org/10.1007/s12149-016-1059-x
  8. 18 F-FDG uptake in the stomach on screening PET/CT: value for predicting Helicobacter pylori infection and chronic atrophic gastritis vol.16, pp.None, 2014, https://doi.org/10.1186/s12880-016-0161-9
  9. Noninvasive detection of gastric cancer vol.37, pp.9, 2014, https://doi.org/10.1007/s13277-016-5129-4
  10. Comparison of DWIBS/T2 image fusion and PET/CT for the diagnosis of cancer in the abdominal cavity vol.14, pp.4, 2014, https://doi.org/10.3892/etm.2017.4987
  11. Evolving role of FDG-PET/CT in prognostic evaluation of resectable gastric cancer vol.23, pp.38, 2014, https://doi.org/10.3748/wjg.v23.i38.6923
  12. Potential Utility of FDG PET-CT as a Non-invasive Tool for Monitoring Local Immune Responses vol.17, pp.4, 2014, https://doi.org/10.5230/jgc.2017.17.e43
  13. The prognostic value of volume-based parameters using 18F-FDG PET/CT in gastric cancer according to HER2 status vol.21, pp.2, 2018, https://doi.org/10.1007/s10120-017-0739-0
  14. The clinical implications of FDG-PET/CT differ according to histology in advanced gastric cancer vol.22, pp.1, 2019, https://doi.org/10.1007/s10120-018-0847-5
  15. CircLMTK2 acts as a novel tumor suppressor in gastric cancer vol.39, pp.5, 2019, https://doi.org/10.1042/bsr20190363
  16. Prognostic Value of Metabolic Information in Advanced Gastric Cancer Using Preoperative 18F-FDG PET/CT vol.53, pp.6, 2014, https://doi.org/10.1007/s13139-019-00622-w
  17. Prognostic Value of Restaging F-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography to Predict 3-Year Post-Recurrence Survival in Patients with Recurrent Gastric Cancer after Curati vol.21, pp.7, 2014, https://doi.org/10.3348/kjr.2019.0672
  18. Dual time point [18F]Flurodeoxyglucose (FDG) Positron Emission Tomography (PET)/Computed Tomography (CT) with water gastric distension in differentiation between malignant and benign gastric lesions vol.7, pp.None, 2014, https://doi.org/10.1016/j.ejro.2020.100268
  19. Metabolic Characteristics and Diagnostic Contribution of 18 F-FDG PET/CT in Gastric Carcinomas vol.29, pp.1, 2014, https://doi.org/10.4274/mirt.galenos.2020.75537
  20. Clinical impact of FDG PET/CT in alimentary tract malignancies: an updated review vol.45, pp.4, 2014, https://doi.org/10.1007/s00261-020-02447-0
  21. Asymptomatic solitary metastasis to the stomach from breast cancer: A case report vol.13, pp.6, 2014, https://doi.org/10.3892/mco.2020.2145
  22. Multiple liver metastases with synchronous gastric and transverse colon cancer diagnosed by gastric perforation successfully treated by SOX plus bevacizumab and completely resected by surgery: a case vol.6, pp.1, 2014, https://doi.org/10.1186/s40792-020-00808-x
  23. Usefulness of [68Ga]Ga-DOTA-FAPI-04 PET/CT in patients presenting with inconclusive [18F]FDG PET/CT findings vol.48, pp.1, 2014, https://doi.org/10.1007/s00259-020-04940-6
  24. Comparison of 68Ga-FAPI and 18F-FDG Uptake in Gastric, Duodenal, and Colorectal Cancers vol.298, pp.2, 2014, https://doi.org/10.1148/radiol.2020203275
  25. Comparison of 18F-FDG PET/CT and 68Ga-FAPI-04 PET/CT in the staging and restaging of gastric adenocarcinoma vol.43, pp.1, 2014, https://doi.org/10.1097/mnm.0000000000001489